(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

DIFFUTAB

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

DIFFUTAB

ST13

US500000076163967

Class

42

Filing

76163967

Registration

2729877

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

35

Latest update

11/16/2023

Classification

Registered

Trademark type

Word

Nice classes

42

Filing date

11/13/2000

Registration date

06/24/2003

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/16/2023

Last transaction

11/16/2023

Responsible office

United States Patent and Trademark Office

Status code

800

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

1985-00-00

First use in commerce

1985-00-00

Drawing code

1

Owner type

16

Owner location

MILAN, IT

Examiner

FRENCH, CURTIS W

Law office

M60

Current location

GENERIC WEB UPDATE

Holders and representatives

Holders

ADARE PHARMACEUTICALS S.R.L.
APTALIS PHARMA S.R.L.
EURAND S.P.A.
Eurand International S.P.A.

Representatives

Victoria Friedman Dennemeyer & Associates, LLC

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

design and development of pharmaceutical formulations

Publications

History of USPTO decisions and trademark events.

35 publications found

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

11/16/2023

RNL2

REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)

11/16/2023

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

11/16/2023

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/16/2023

E89R

TEAS SECTION 8 & 9 RECEIVED

05/22/2023

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

06/24/2022

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

11/18/2015

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

06/25/2013

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

06/25/2013

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

06/25/2013

E89R

TEAS SECTION 8 & 9 RECEIVED

06/20/2013

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

01/25/2012

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

01/22/2010

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

01/22/2010

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

07/15/2009

PLGL

ASSIGNED TO PARALEGAL

06/16/2009

E815

TEAS SECTION 8 & 15 RECEIVED

06/12/2009

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/03/2009

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

05/27/2009

CFIT

CASE FILE IN TICRS

02/14/2008

R.PR

REGISTERED-PRINCIPAL REGISTER

06/24/2003

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

04/25/2003

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/21/2003

MAIL

PAPER RECEIVED

02/21/2003

CNRT

NON-FINAL ACTION MAILED

09/06/2002

DOCK

ASSIGNED TO EXAMINER

08/30/2002

SUPC

STATEMENT OF USE PROCESSING COMPLETE

08/28/2002

MAIL

PAPER RECEIVED

08/07/2002

IUAF

USE AMENDMENT FILED

06/18/2002

NOAM

NOA MAILED - SOU REQUIRED FROM APPLICANT

02/05/2002

PUBO

PUBLISHED FOR OPPOSITION

11/13/2001

NPUB

NOTICE OF PUBLICATION

10/24/2001

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/02/2001

CNEA

EXAMINER'S AMENDMENT MAILED

03/26/2001

DOCK

ASSIGNED TO EXAMINER

03/22/2001

Continuous trademark protection

Get notified about every new filing that threatens DIFFUTAB or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.